Erenumab

Evidence Level: N/A

Predicted Indications: 0

Erenumab

Pharmacist Assessment Report

Erenumab: Known uses and market status in India

Summary

All candidates produced by the TxGNN model for Erenumab (score ≥ 0.99) that can be traced to a source are already known uses, so there is currently no new predicted indication. The one known use found is related to an approved indication in the same disease category. It is not itself recorded as approved.

Quick overview

Item	Content
New predicted indications	None (all traceable model candidates are known uses)
Known uses among model candidates	1
Evidence level	Not applicable
India Market Status	Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data
Number of Listed Products	1 (valid: 1)

Known uses among the model’s candidates

Approved (supported by a licence or label)

Indication	Source
none	none

Indication	Approved category
migraine with brainstem aura	migraine

Relations recorded in the knowledge graph (no approval found)

Indication
none

India Market Information

Licence	Product	Dosage form	Status
214766	Suviray Injection	vial of 1 Solution for Injection	Valid

Safety Considerations

Drug Interactions: The interaction query completed, with one pharmacology entry (target: CGRP receptor), which describes the drug’s target and not a drug-drug interaction. No interacting drugs with severity ratings were identified.
Cardiovascular and cerebrovascular safety: Published analyses (PMIDs 36942409, 34928306, 42390441) examined vascular risk in people with migraine with aura. These are relevant to a subtype with elevated vascular risk, but they do not replace label-based safety review.

Please refer to the package insert for other safety information, including warnings and contraindications.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.